FDA
-
-
-
-
-
-
-
Gilead Sciences (GILD), Galapagos NV (GLPG) Amend Development Agreement for Jyselec
-
-
-
-
-
-
-
Galapagos (GLPG) announces Gilead (GILD) received CRL for filgotinib for treatment of moderately to severely active rheumatoid arthritis
-
-
-
-
-
-
-
Gilead Sciences (GILD), Galapagos NV (GLPG) Phase 2B/3 Trial of Filgotinib Met All Primary Endpoints
-
-
-
-
-
-
-
Gilead Sciences (GILD), Galapagos (GLPG) to Present New Data on Filgotinib at 2019 ACR/ARP Annual Meeting
-
-
-
-
-
-
-
Proteostasis Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
GILEAD AND GALAPAGOS TO PRESENT LATEST DATA ON FILGOTINIB AT THE ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY (EULAR 2019)
-
-
-
-
-
-
-
Galapagos receives Fast Track designation from FDA for GLPG1972/S201086 in osteoarthritis
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

